Mechanics Bank Trust Department buys $724,315 stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Mechanics Bank Trust Department scooped up 950 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 7,106 shares of Gilead Sciences which is valued at $724,315.Gilead Sciences makes up approximately 0.28% of Mechanics Bank Trust Department’s portfolio.

Gilead Sciences closed down -0.61 points or -0.60% at $100.72 with 85,85,754 shares getting traded on Wednesday. Post opening the session at $101.3, the shares hit an intraday low of $100.15 and an intraday high of $101.78 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Legacy Private Trust boosted its stake in GILD in the latest quarter, The investment management firm added 215 additional shares and now holds a total of 24,945 shares of Gilead Sciences which is valued at $2,542,644. Gilead Sciences makes up approx 0.38% of Legacy Private Trust’s portfolio.Tnb Financial boosted its stake in GILD in the latest quarter, The investment management firm added 2,780 additional shares and now holds a total of 57,305 shares of Gilead Sciences which is valued at $5,632,508. Gilead Sciences makes up approx 1.68% of Tnb Financial’s portfolio.Independent Portfolio Consultants boosted its stake in GILD in the latest quarter, The investment management firm added 785 additional shares and now holds a total of 21,768 shares of Gilead Sciences which is valued at $2,139,577. Gilead Sciences makes up approx 0.59% of Independent Portfolio Consultants’s portfolio.Stonebridge Capital Management Inc boosted its stake in GILD in the latest quarter, The investment management firm added 14,530 additional shares and now holds a total of 22,470 shares of Gilead Sciences which is valued at $2,208,576. Gilead Sciences makes up approx 0.93% of Stonebridge Capital Management Inc’s portfolio.Partnerre Asset Management Corp reduced its stake in GILD by selling 498 shares or 5.12% in the most recent quarter. The Hedge Fund company now holds 9,220 shares of GILD which is valued at $883,553. Gilead Sciences makes up approx 0.47% of Partnerre Asset Management Corp’s portfolio.

On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.